{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:07:29Z","timestamp":1700543249061},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Scientific Foundation of China","doi-asserted-by":"crossref","award":["82001986"],"award-info":[{"award-number":["82001986"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Outstanding Youth Science Foundation of Yunnan Basic Research Project","award":["202101AW070001"],"award-info":[{"award-number":["202101AW070001"]}]},{"name":"the Yunnan Basic Research Project","award":["202201AT070010"],"award-info":[{"award-number":["202201AT070010"]}]},{"name":"Innovation Team of Kunming Medical University","award":["CXTD202110"],"award-info":[{"award-number":["CXTD202110"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To explore the correlation between the initial recurrence site and survival after recurrence (PRS) in non-small cell lung cancer (NSCLC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected 588 stages I\u2013III NSCLC patients with recurrence after radical resection in Yunnan Cancer Hospital from January 2013 to December 2018. We used Kaplan\u2013Meier survival curves to compare PRS in patients with different site recurrences. The univariate and multivariate Cox proportional hazard models were used to analyze the impact of the initial recurrence site on PRS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The recurrence site included the lung (<jats:italic>n<\/jats:italic>\u2009=\u2009109), brain (<jats:italic>n<\/jats:italic>\u2009=\u2009113), bone (<jats:italic>n<\/jats:italic>\u2009=\u200979), abdomen (<jats:italic>n<\/jats:italic>\u2009=\u200928), pleura (<jats:italic>n<\/jats:italic>\u2009=\u200924), lymph node (<jats:italic>n<\/jats:italic>\u2009=\u200981), and multisite (<jats:italic>n<\/jats:italic>\u2009=\u2009154). In the total population, patients with multisite recurrence had substantially worse PRS (24.8\u00a0months, 95% confidence interval [CI]: 17.46\u201332.20) than that of patients without multiple sites recurrence (42.2\u00a0months, 95% <jats:italic>CI<\/jats:italic> 32.24\u201352.10) (<jats:italic>P<\/jats:italic>\u2009=\u20090.026). However, patients with lung recurrence had better RFS (63.1\u00a0months, 95% <jats:italic>CI<\/jats:italic> 51.13\u201374.00) than those who did not (31.0\u00a0months, 95% <jats:italic>CI<\/jats:italic> 25.10\u201336.96) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In adenocarcinoma, patients with pleural recurrence had substantially worse PRS (21.3\u00a0months, 95% <jats:italic>CI<\/jats:italic> 15.07\u201327.46) than that of patients without pleural recurrence (46.9\u00a0months, 95% <jats:italic>CI<\/jats:italic> 35.07\u201358.80) (<jats:italic>P<\/jats:italic>\u2009=\u20090.031). Multivariate Cox proportional hazards regression analysis revealed that lung recurrence (<jats:italic>HR<\/jats:italic> 0.58, 95% <jats:italic>CI<\/jats:italic> 0.40\u20130.82; <jats:italic>P<\/jats:italic>\u2009=\u20090.003) was independent protective prognostic factor for PRS in the total population, while pleural recurrence (<jats:italic>HR<\/jats:italic> 2.18, 95% <jats:italic>CI<\/jats:italic> 1.14\u20134.17; <jats:italic>P<\/jats:italic>\u2009=\u20090.018) was independent adverse prognostic factors for PRS in adenocarcinoma patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The initial recurrence site was associated with PRS in NSCLC patients. Identification of recurrence sites could guide the subsequent treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-023-03252-x","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T03:02:13Z","timestamp":1700535733000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of initial recurrence site on the prognosis of different tissue types of non-small cell lung cancer: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yanli","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiming","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingwan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaojuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjiang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"3252_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/1078155220904133","volume":"26","author":"O Tanriverdi","year":"2020","unstructured":"Tanriverdi O, Alkan A, Ozseker B, Solak-Ozseker H, Kilinc RM. Synchronous duodenum and descending colon metastasis from primary lung neuroendocrine small-cell carcinoma: a case report and review of the literature. J Oncol Pharm Pract. 2020;26:1524\u20139.","journal-title":"J Oncol Pharm Pract"},{"key":"3252_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1186\/s12885-018-4849-9","volume":"18","author":"T Isaka","year":"2018","unstructured":"Isaka T, Nakayama H, Ito H, Yokose T, Yamada K, Masuda M. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. BMC Cancer. 2018;18:959.","journal-title":"BMC Cancer"},{"key":"3252_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.athoracsur.2012.01.004","volume":"93","author":"C Endo","year":"2012","unstructured":"Endo C, Sakurada A, Notsuda H, Noda M, Hoshikawa Y, Okada Y, Kondo T. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012;93:1061\u20138.","journal-title":"Ann Thorac Surg"},{"key":"3252_CR4","first-page":"204","volume":"7","author":"I Yoshino","year":"2001","unstructured":"Yoshino I, Yohena T, Kitajima M, Ushijima C, Nishioka K, Ichinose Y, Sugimachi K. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg. 2001;7:204\u20139.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"3252_CR5","doi-asserted-by":"crossref","unstructured":"Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Williams BA, Pairolero PC. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007; 83:409\u2013417; discussioin 417\u2013408.","DOI":"10.1016\/j.athoracsur.2006.08.046"},{"key":"3252_CR6","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1378\/chest.12-1717","volume":"143","author":"Y Shimada","year":"2013","unstructured":"Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M, Usuda J, Kajiwara N, Ohira T, Ikeda N. Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer. Chest. 2013;143:1626\u201334.","journal-title":"Chest"},{"key":"3252_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/ejcts\/ezab442","volume":"61","author":"T Isaka","year":"2022","unstructured":"Isaka T, Ito H, Nakayama H, Yokose T, Saito H, Masuda M. Impact of the initial site of recurrence on prognosis after curative surgery for primary lung cancer. Eur J Cardiothorac Surg. 2022;61:778\u201386.","journal-title":"Eur J Cardiothorac Surg"},{"key":"3252_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ejcts.2008.05.016","volume":"34","author":"T Nakagawa","year":"2008","unstructured":"Nakagawa T, Okumura N, Ohata K, Igai H, Matsuoka T, Kameyama K. Postrecurrence survival in patients with stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;34:499\u2013504.","journal-title":"Eur J Cardiothorac Surg"},{"key":"3252_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.33160\/yam.2017.12.001","volume":"60","author":"Y Kubouchi","year":"2017","unstructured":"Kubouchi Y, Kidokoro Y, Ohno T, Yurugi Y, Wakahara M, Haruki T, Nakamura H. Prognostic factors for post recurrence survival in resected pathological stage I non-small cell lung cancer. Yonago Acta Med. 2017;60:213\u20139.","journal-title":"Yonago Acta Med"},{"key":"3252_CR10","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1200\/JCO.2015.60.9818","volume":"33","author":"H Ujiie","year":"2015","unstructured":"Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, Huang J, Travis WD, Rizk NP, Rudin CM, et al. Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival. J Clin Oncol. 2015;33:2877\u201384.","journal-title":"J Clin Oncol"},{"key":"3252_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12885-020-6621-1","volume":"20","author":"C Wang","year":"2020","unstructured":"Wang C, Wu Y, Shao J, Liu D, Li W. Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer. BMC Cancer. 2020;20:150.","journal-title":"BMC Cancer"},{"key":"3252_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1158\/1055-9965.EPI-18-0966","volume":"28","author":"BA Peters","year":"2019","unstructured":"Peters BA, Hayes RB, Goparaju C, Reid C, Pass HI, Ahn J. The microbiome in lung cancer tissue and recurrence-free survival. Cancer Epidemiol Biomark Prev. 2019;28:731\u201340.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3252_CR13","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1111\/1759-7714.14601","volume":"13","author":"M Kong","year":"2022","unstructured":"Kong M, Lim YJ. Chronic hyperglycemia is an adverse prognostic factor for locoregional recurrence-free survival in small cell lung cancer patients treated with radical radiotherapy. Thoracic Cancer. 2022;13:2633\u201340.","journal-title":"Thoracic Cancer"},{"key":"3252_CR14","doi-asserted-by":"crossref","unstructured":"Xu J, Zeng H, Zhang G, Li R, Yuan Z, Ren J, Huang Y, Ren F, Zhang H, Fei K, et al. Development and validation of a nomogram based on preoperative variables for predicting recurrence\u2010free survival in stage IA lung adenocarcinoma.\u00a0Thorac\u00a0Cancer. 2023;14:3108\u201318.","DOI":"10.1111\/1759-7714.15099"},{"key":"3252_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.suronc.2013.04.002","volume":"22","author":"D Fedor","year":"2013","unstructured":"Fedor D, Johnson WR, Singhal S. Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes. Surg Oncol. 2013;22:156\u201361.","journal-title":"Surg Oncol"},{"key":"3252_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/COC.0000000000000656","volume":"43","author":"H Matsuguma","year":"2020","unstructured":"Matsuguma H, Nakahara R, Wakamatsu I, Kishikawa T, Sugiyama T, Nakamura Y, Kasai T, Kamiyama Y, Hoshi N, Inoue K, et al. Definitive local therapy for oligo-recurrence in patients with completely resected non-small cell lung cancer. Am J Clin Oncol. 2020;43:210\u20137.","journal-title":"Am J Clin Oncol"},{"key":"3252_CR17","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1002\/cncr.24333","volume":"115","author":"Y Oh","year":"2009","unstructured":"Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, Sawaya R, Komaki R, Stewart DJ, Karp DD. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009;115:2930\u20138.","journal-title":"Cancer"},{"key":"3252_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2015.02.012","volume":"88","author":"KL Wu","year":"2015","unstructured":"Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015;88:187\u201394.","journal-title":"Lung Cancer"},{"key":"3252_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3892\/ol.2012.792","volume":"4","author":"K Nakazawa","year":"2012","unstructured":"Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, Hizawa N. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012;4:617\u201320.","journal-title":"Oncol Lett"},{"key":"3252_CR20","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1016\/j.cllc.2019.06.020","volume":"20","author":"S Sridhar","year":"2019","unstructured":"Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, et al. Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients. Clin Lung Cancer. 2019;20:e601\u20138.","journal-title":"Clin Lung Cancer"},{"key":"3252_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihimaki","year":"2014","unstructured":"Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78\u201384.","journal-title":"Lung Cancer"},{"key":"3252_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JTO.0b013e3181949c6a","volume":"4","author":"K Okubo","year":"2009","unstructured":"Okubo K, Bando T, Miyahara R, Sakai H, Shoji T, Sonobe M, Fujinaga T, Sato K, Wada H, Tanaka T. Resection of pulmonary metastasis of non-small cell lung cancer. J Thorac Oncol. 2009;4:203\u20137.","journal-title":"J Thorac Oncol"},{"key":"3252_CR23","doi-asserted-by":"crossref","unstructured":"Walsh GL, O'Connor M, Willis KM, Milas M, Wong RS, Nesbitt JC, Putnam JB, Jr., Lee JJ, Roth JA. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 1995, 60:1563\u20131570; discussion 1570\u20131562.","DOI":"10.1016\/0003-4975(95)00893-4"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-03252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-023-03252-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-03252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T03:40:06Z","timestamp":1700538006000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-023-03252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3252"],"URL":"https:\/\/doi.org\/10.1186\/s12957-023-03252-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"23 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital & Yunnan Cancer Center) before the commencement of the research. All participants had implemented informed consent and signed the informed consent before the investigation. We confirm that all methods (diagnosis, staging, and treatment of lung cancer) were carried out by the \u201clung cancer clinical practice guidelines\u201d from the National Comprehensive Cancer Network (NCCN) of the USA. The methods in this study were followed by the relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}